Research unravels Improvement of melanoma treatment by blocking an enzyme

Immune suppression

The field of cancer immunotherapy has witnessed exciting therapeutic advances in the last decade, particularly in the treatment of melanoma, a highly aggressive form of skin cancer. However, approximately 65% of melanoma patients still do not respond to immune checkpoint blockade (ICB) therapies. The immunosuppression induced by tumor-associated macrophages (TAMs) may be pivotal in this process. TAMs have been shown to impede immune system function, thereby fostering tumor growth and metastasis dissemination. Thus, reprogramming TAM phenotype away from their immunosuppressive state might boost cancer treatments.

New work by the team of Prof. Max Mazzone (VIB-KU Leuven) and colleagues zooms in on a specific enzyme known as hematopoietic prostaglandin D2 synthase (HPGDS), which is produced by TAMs. HPGDS promotes the formation of a metabolite called prostaglandin D2 (PGD2), which, in turn, helps cancer cells to resist treatment by blocking the activity of T-cells, which are vital for attacking tumors.

Reprogramming TAMs

“By analyzing the expression of genes related to the immune response in patients who responded to immune checkpoint blockade therapies compared to those who did not, we found that HPGDS levels were high in non-responding patients during treatment, whereas were downregulated if the treatment was working and T-cells were then activated against the tumor” says Dr. Rosa Trotta, first author of the study.

By employing genetic deletion of HPGDS in macrophages and using pharmacological inhibitors in mouse and humanized models, the researchers proved a remarkable shift in the macrophages' behavior from promoting tumor growth to supporting a more robust and anti-tumoral immune response.

“Targeting HPGDS not only enhanced the recruitment and activation of T-cells per se,” says Prof. Max Mazzone, “but also showed promise in overcoming resistance to existing therapies. Our findings suggest that blocking HPGDS or the two downstream receptors may be a new potential strategy for improving treatment options for melanoma patients and perhaps others facing similar challenges.”

This study suggests that HPGDS inhibitors or PGD2 receptor blockers could serve as new therapeutic agents, either alone or in combination with existing treatments for melanoma and other cancers (i.e., pancreatic ductal adenocarcinoma) that show similar resistance mechanisms. As the research progresses, the team emphasizes the need for further studies to validate these findings in clinical settings.

Reference:

Trotta, R., et al. (2025). Activated T cells break tumor immunosuppression by macrophage re-education. Cancer Discovery. doi.org/10.1158/2159-8290.cd-24-0415.